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Abstract
Overexpression of the epidermal growth factor receptor
(EGFR) in epithelial tumors is associated with poor
prognosis and is the target for a number of cancer
therapeutics. Monoclonal antibody (mAb) 806 is a novel
anti–EGFR antibody with significant therapeutic effi-
cacy in tumor models when used as a single agent, and
displays synergistic antitumor activity in combination
with other EGFR therapeutics. Unlike other EGFR
antibodies, mAb 806 is selective for tumor cells and
does not bind to normal tissue, making it an ideal
candidate for generation of radioisotope or toxin con-
jugates. Ideally, antibodies suited to these therapeutic
applications must bind to and actively internalize their
cognate receptor. We investigated the intracellular
trafficking of fluorescently tagged mAb 806 in live cells
and analyzed its biodistribution in a tumor xenografted
nude mouse model. Following binding to EGFR, mAb
806 was internalized through dynamin-dependent,
clathrin-mediated endocytosis. Internalized mAb 806
localized to early endosomes and subsequently traf-
ficked to and accumulation in lysosomal compart-
ments. Furthermore, biodistribution analysis in nude
mice showed specific uptake and retention of radio-
labeled mAb 806 to human tumor xenografts. These
results highlight the potential use of mAb 806 for gen-
eration of conjugates suitable for diagnostic and thera-
peutic use in patients with EGFR-positive malignancies.
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Introduction
The epidermal growth factor receptor (EGFR) is overex-
pressed in a variety of epithelial malignancies and, there-
fore, has become an attractive target for numerous anti–
cancer therapeutics [1]. These have included tyrosine ki-
nase inhibitors and antibodies [2,3], with the first anti–
EGFR therapeutic, Cetuximab, being recently approved
for use in colorectal cancer patients [4]. Whereas these
agents continue to show promising efficacy in a number of
advanced clinical trials, targeting of normal tissue such as the
liver, skin, and gastrointestinal tract, limits their use and
restricts antibodies to naked therapy, whereby antibody alone
elicits a therapeutic effect [5–7].
We have previously described a novel anti–EGFR antibody,
monoclonal antibody (mAb) 806, which targets the EGFR
deletion variant, de2–7 EGFR as well as wild-type (wt) EGFR
expressed in cells overexpressing the receptor [8–15]. MAb
806 does not bind to normal tissue expressing physiological
levels of the receptor, including skin and liver, as demonstrated
by extensive immunohistochemistry studies, as well as our
first-in-man clinical trial of ch806 [11,16]. This unique specificity
profile of mAb 806 arises from its ability to recognize an epitope
that is exposed only during the transition of the receptor
between a tethered inactive conformation to an untethered
active conformation [17,18]. In addition, when the EGFR is
overexpressed, untethering appears to occur at an increased
rate, possibly due to changes in glycosylation [14]. In cells
expressing the truncated de2–7 EGFR, the epitope is contin-
uously exposed and therefore mAb 806 is able to bind consti-
tutively. As such, this epitope is different to all other epitopes
targeted by current anti–EGFR antibodies and is therefore not
accessible in normal human tissues when the receptor is
expressed at physiological levels [17,18].
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In vivo therapeutic evaluation of mAb 806 alone and in
combination with other anti–EGFR agents also shows sub-
stantial antitumor effects in de2–7 EGFR expressing and wt
EGFR overexpressing tumors. No activity against cells
expressing normal levels of EGFR were detected [8,12,15].
Given the unique specificity of mAb 806 and its ability to elicit
a significant antitumor response, we investigated its potential
for targeted drug delivery by assessing its internalization
profile and biodistribution in tumor-bearing mice.
Indeed, tumor-specific antibodies which are able to illicit
downregulation of receptor from the cell surface, thereby
potentially attenuating receptor activity, may have greater effi-
cacy than those that do not [19,20]. We have recently shown
that treatment of de2–7 EGFR expressing tumors with mAb
806 in combination with another prototypical anti–EGFR
antibody (mAb 528) results in substantial receptor downregu-
lation, leading toa significant antitumor response [15].Coupled
with the unique specificity of mAb 806, its ability to internalize
following binding to the receptor can be used to generate
immunoconjugates which would allow for targeted delivery of
radiation or toxins to tumor cells without toxicity to normal
tissue [21–24]. Such a procedure would not be possible with
current therapeutic agents targeting the wt EGFR, such as
Cetuximab, due to extensive uptake and subsequent toxicity in
organs such as the liver, skin, and gastrointestinal tract.
This study investigates the mechanism of mAb 806
internalization following binding to EGFR in cells overex-
pressing the wt receptor, as well as its intracellular trafficking
profile. Biodistribution analysis with two different radioiso-
topes was also performed to ascertain tissue uptake and
tumor cell retention.
Materials and methods
Cell Lines and Reagents
The epidermoid carcinoma cell line, A431 [10], and squa-
mous carcimona cell line, HN5 [14,25], have been described
previously. The mAbs 806 and 528 have also been described
previously and were produced in the Biological Production
Facility (Ludwig Institute for Cancer Research, Melbourne,
Australia). Other monoclonal antibodies against CD107a
(also known as lysosomal-associated membrane protein 1
(LAMP1)) and early endosome autoantigen 1 (EEA1) were
purchased from Pharmingen (San Diego, CA) and Trans-
duction Laboratories (San Diego, CA), respectively. Cy2-
conjugated anti–mouse secondary antibody and unlabeled
goat anti–mouse blocking Fab fragment were purchased from
Jackson ImmunoResearch Laboratories (West Grove, PA).
Biotinylated epidermal growth factor complexed to Alexa 488
and transferrin (Tfn) labeled with fluorescein isothiocyanate
(FITC) were purchased from Molecular Probes (Eugene, OR).
Immunofluorescence
MAb 806 or 528 was directly labeled with cyanine 3
(Cy3) dye using the Cy3 Monoclonal Antibody Labeling kit
(Amersham Pharmacia Biotech UK Ltd, Buckinghamshire,
UK) according to the manufacturer’s instructions. Successful
labeling of antibody was determined through flow cytometry
analysis of binding to A431; all analyses were performed
in triplicate. Immunofluorescence was conducted on A431
cells grown on 12-mm glass coverslips or 12-mm Biocoat
Cell Environments poly-D-lysine coverslips (Becton Dickinson
Labware, Bedford, MA). Cy3-conjugated mAb 806 and 528
were used at concentrations of 5 and 2 mg/ml, respectively,
and surface labeling was carried out at 4jC for 20 minutes.
Internalization of surface-bound antibody was initiated by
incubation in prewarmed (37jC) serum-free media. At the
appropriate time points, coverslips were removed, washed
in ice-cold BSA/PBS before fixation in 4% paraformaldehyde
(PFA). Cells were then permeabilized with 0.1% Triton X-100
and incubated with unlabelled goat anti–mouse Fab frag-
ment to block all existing mouse binding sites. Samples were
then incubated with the appropriate antibody to intracellular
organelles (i.e., LAMP1 or EEA1) followed by labeling with
Cy2-conjugated secondary antibody. Samples were subse-
quently mounted in Fluoromount G (Southern Biotechnology,
Birmingham, AL) and analyzed with an epifluorescent micro-
scope (Olympus America Inc., Melville, NY) using appropriate
wavelength settings.
Cellular Transfection
DNA vectors for green fluorescent protein (GFP)–tagged
lysosomal glycoprotein 120 (lgp-120–GFP) and dominant-
negative dynamin K44A (DynK44A–GFP) were kindly pro-
vided by Prof. I. Mellman and Prof. P. De Camilli, from the
Department of Cell Biology, Yale University School of
Medicine. Cells grown in glass-bottom microwell dishes
(MatTek Corp., Ashland, MA) were transfected overnight
using a reagent (Lipofectamine; Invitrogen Life Technolo-
gies, Victoria, Australia) following the manufacturer’s instruc-
tions. Epifluorescent imaging was performed 24 hours after
successful transfection.
Time-Lapse Microscopy
Time-lapse series were acquired at 37jC on an inverted
microscope (Olympus 1X70; Olympus America Inc., Melville,
NY), equipped with a 60 oil immersion objective, NA 1.45,
and a 16-bit charge-coupled device camera (Till Photonics
LLC, Pleasanton, CA) using 1  1 or 2  2 binning. A dual
dichroic GFP/Texas red filter (Chroma, Rockingham, VT)
allowed for simultaneous detection of GFP and/or red fluo-
rescent protein (RFP). Switching between the excitation
wavelengths was controlled by TILLvisION software (Till
Photonics LLC). Exposure times were 200 and 400 ms for
GFP and RFP channels, respectively. Time-lapse sequences
corresponding to roughly one frame per 7 seconds (for 1 hour)
were subsequently acquired and merged as RGBs using
TILLvisION. Series were exported as tagged image file for-
mat and processed in Adobe Photoshop (Adobe Systems
Inc., San Jose, CA). Videos of representative experiments are
in the Supplemental data.
Quantification of Mean Ratio of Fluorescence Intensity
Using Andor IQ image analysis software (Andor Technol-
ogy, South Windsor, CT), regions of interest corresponding
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to labeled antibody were selected from the intracellular
region and the plasma membrane of each cell. Mean inten-
sity values for both areas of interest over the course of the
60-minute time-lapse movies were monitored every minute
and the ratio of intracellular to membrane fluorescence in-
tensity was calculated. The average ratio at each time point
was subsequently calculated for four to six cells per treat-
ment and plotted over time.
Electron Microscopy
Cells were preincubated with mAb 806 antibody on ice
before induction of internalization at 37jC for 0, 5, 10, and
30 minutes. Samples were subsequently fixed in 4% PFA in
0.25 M Hepes (pH 7.4), for 1 hour at room temperature,
followed by fixation in 8% PFA in the same buffer, overnight
at 4jC. Cell pellets were frozen in liquid nitrogen and cryosec-
tioned using an ultramicrotome (Leica Ultracut UCT; Leica
Microsystems Inc., Bannockburn, IL). Sections were labeled
using a rabbit anti–mouse antibody, followed by protein A
conjugated to 5-nm gold particles. Sections were embedded
in 1.8% methyl cellulose and 0.5% uranyl acetate, air-dried,
examined in a transmission electron microscope (Tecnai 12
Biotwin; FEI Company, Hillsboro, OR), and photographed.
Biodistribution of 125I- and 111In–CHX-AW-DTPA–Labeled
mAb 806 In Vivo
A comparison of the biodistribution and localization of
125I- and 111In–CHX-AW-DTPA– [26] labeled mAb 806 was
performed using a radiolabeling procedure previously de-
scribed [27]. Radiolabeling was performed on the day of
injection into mice. Before injection, radiopurity, specific
activity, binding ability, and number of antibody molecules
bound per cell for the final radiolabeled product were tested.
Biodistribution analysis was conducted in BALB/c nude
mice bearing established (70 mm3) subcutaneous A431
tumors (n = 24). Animals were injected IV through tail vein
injection with either mAb 806 or mAb 100-310 (an isotype-
matched mAb directed to human A33 antigen) labeled with
5 mCi of both 125I- and 111In–CHX-AW-DTPA (total, 10 mg of
antibody and 10 mCi of radioactivity) suspended in 100 ml of
sterile PBS. Groups of four tumor-bearing mice injected with
radiolabeled mAb 806 were sacrificed at 4, 24, 48, 72, and
168 hours after injection of radiolabeled antibody. One group of
four mice injected with radiolabeled 100-310 was sacrificed
24 hours after antibody injection. Mice were bled through
cardiac puncture and tumors and organs (brain, lung, liver,
stomach, spleen, and kidney) were immediately removed,
blotted dry, and weighed. All samples were counted in a dual
chamber gamma scintillation counter (Cobra II, Auto-gamma;
Packard Instruments, Canberra, Australia) using a dual tracer
program with standard windows set for each isotope, 15 to
75 keV for 125I and 120 to 460 keV for 111In. Standards pre-
pared from the injected material were counted each time with
tissues and tumors, enabling calculations to be corrected
for the physical decay of the isotopes. Results of labeled anti-
body distribution over time were expressed as the percentage
injected dose/gram (% ID/g) [(cpm tissue sample / cpm stan-
dard)  100 /weight in grams] and as tumor/blood ratios.
Results
Binding of Cy3 Dye–Conjugated mAb 806 and 528 to
Cell Lines
The binding specificity of mAb 806 and 528 conjugated
with Cy3 dye to wt EGFR and de2–7 EGFR was assessed
using A431 and U87MG.D2–7 cells, respectively. Binding to
U87MG.D2–7 cells was included as a positive control for
mAb 806 given its relatively low binding to A431 cells. FACS
analysis shows that both antibodies retained their specificity
following conjugation to Cy3. Low but highly reproducible
binding of mAb 806–Cy3 to A431 cells was observed by
FACS analysis (Figure 1E ) and was consistent with previous
observations where mAb 806 bound f 10% of the 2  106
EGFRs/cell [8,10]. As expected, the anti–EGFR 528–Cy3
antibody showed strong binding to A431 cells (Figure 1F ).
An isotype-matched IgG2b antibody (100-310) conjugated to
Cy3 was used as a negative control (Figure 1, A, D, and G).
Neither antibody bound to the negative control murine he-
mopoietic cell line, BaF/3 (Figure 1, B and C), which does not
express endogenous wt or de2–7 EGFR [28]. These results
are consistent with those obtained with unconjugated anti-
body [8], suggesting that direct conjugation with fluorescent
tags do not alter the specificity of these antibodies.
Internalization of mAb 806 following Binding to a Subset of
EGFR Expressed in A431 and HN5 Cells
MAb 806–Cy3 internalization, following binding to 10% of
wt EGFR recognized by this antibody in A431 (Figure 2) and
HN5 cells (Figure W1), was assessed. Internalization of mAb
806 was also compared to that of mAb 528–Cy3 that binds
to the bulk of the wt EGFR. Internalization of antibody
preincubated at 4jCwas observed by time-lapse microscopy
for 1 hour at 37jC (Figure 2A and Figure W1A). Rapid
internalization of mAb 806–Cy3 was indicated by the ap-
pearance of small intracellular punctuate structures (Fig-
ure 2A and Figure W1A; 15 minutes; arrows). Over time,
these structures increased in number and accumulated
intracellularly. Quantification of the mean fluorescence inten-
sity ratio between the intracellular region versus the cell
surface and vice versa, over the time course of 60 minutes
was calculated (Figure 2B and Figure W1B). This ratio
steadily increased over time, highlighting the gradual accu-
mulation of internalized antibody within intracellular compart-
ments (Figure 2B and Figure W1B; intracellular/membrane).
Concurrently, the ratio of membrane to intracellular fluores-
cence was seen to decrease with time, consistent with the
progressive removal of antibody from the cell surface and its
concomitant intracellular accumulation (Figure 2B and Fig-
ure W1B). Isotype control antibody tagged with Cy3 did not
bind to cells and was not internalized (data not shown).
Dynamin-Dependent Internalization of mAb 806
The dependence of mAb 806 internalization on the pres-
ence of functional dynamin, aGTPase essential for the fission
of endocytic vesicles from the plasma membrane [29,30],
was assessed in A431 cells expressing dominant-negative
dynamin K44A tagged with GFP (DynK44A–GFP) [31,32].
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DynK44A–GFP–transfected and –nontransfected cells
were continuously imaged for 60 minutes following incu-
bation with mAb 806–Cy3 (Figure 3). In nontransfected
cells, internalized mAb 806–Cy3 showed a characteristic
intracellular accumulation (Figure 3A). This is also shown by
the steady increase over time in the ratio of intracellular to
membrane fluorescence (and concurrent decrease in mem-
brane to intracellular fluorescence ratio; Figure 3B). When
endocytosis was blocked by the expression of dominant-
negative dynamin K44A (Figure 3, asterisk), there was no
Figure 1. Flow cytometric analysis of BaF/3, A431, and U87MG.D2–7 cell lines. Cells were incubated with either an irrelevant IgG2b, mAb 806, or mAb 528 by
methods previously described [17] following conjugation with Cy3 dye. (A–C) BaF/3 cells were directly labeled with IgG2b /Cy3, mAb 806/Cy3, and mAb 528/Cy3,
respectively; binding was visualized by flow cytometry. (D and E) A431 cells were directly labeled with IgG2b /Cy3, mAb 806/Cy3, and mAb 528/Cy3, respectively;
binding was visualized by flow cytometry. (G and H) U87MG.D2–7 cells were directly labeled with IgG2b /Cy3, mAb 806/Cy3, and mAb 528/Cy3, respectively;
binding was visualized by flow cytometry. All analyses were performed in triplicate; data are representative of binding observed in all samples.
Figure 2. Time-lapse microscopy of antibody internalization in A431 cells. (A) Cells were preincubated with mAb 806–Cy3 at 4jC (0 minute). Internalized antibody
is indicated by arrows in sequential images representing 15, 30, and 60 minutes of incubation at 37jC. (B) Mean ratio of fluorescence intensity between the
intracellular region and cell surface. The mean fluorescence of the intracellular region (dashed circle) and cell membrane (dashed rectangle) were calculated (n = 5)
and the average ratio of intracellular to membrane (black plot) and membrane to intracellular (red plot) fluorescence ± SEM plotted over time (n = 5). Scale bar,
20 m. Refer to Supplemental data for Video W1.
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net intracellular accumulation of fluorescence. Furthermore,
the constant membrane to intracellular fluorescence ratio
indicates a failure in the clearance of cell surface–localized
antibody. This result indicates that 806 internalization is de-
pendent on the presence of functional dynamin, a key regu-
lator of scission of clathrin-coated vesicles.
Endosomal Localization of mAb 806 in A431 Cells
We initially compared the internalization of mAb 806
following binding to the wt EGFR in A431 cells to that of
Tfn. The recycling of Tfn in A431 cells has been extensively
characterized previously [33,34].
Cells simultaneously preincubated with mAb 806–Cy3
and Tfn–FITC were allowed to internalize at 37jC (Fig-
ure 4A; 2 minutes). Labeled mAb 806 (red) was present
intracellularly as small vesicles (yellow arrowheads), as well
as on the cell surface. FITC-labeled Tfn (green) is present
both at the plasma membrane, where it colocalizes with
membrane-bound mAb 806 (areas of yellow signal ) and
intracellularly (green signal ).
Longer incubation at 37jC, increased the number of mAb
806 punctate moving into the cytoplasm which colocalized
with Tfn-FITC, suggesting they at least transiently localize
to endocytic vesicles and/or compartments (Figure 4A;
30 minutes; arrows indicating yellow signal ). Colocalization
between these two agents suggests that mAb 806 is inter-
nalized through similar mechanisms to that of Tfn and
localized within similar intracellular structures.
The intracellular compartments to which endocytosed
mAb 806 localized to was identified through dual labeling with
an antibody against EEA1. After 15 and 30 minutes of in-
cubation at 37jC, internalized mAb 806 was visualized as
small punctuate, cytoplasmic vesicular structures, which par-
tially colocalized with EEA1 (Figure 4B; 15 and 30 minutes;
arrows), suggesting that these structures containing internal-
ized mAb 806 are predominantly early endosomes. Following
60 minutes incubation at 37jC, the extent of colocalization
Figure 3. Time-lapse of mAb 806 internalization in A431 cells expressing dynamin K44A–GFP. (A) Cells were transiently transfected with DynK44A–GFP (red
asterisk). Panels representing images at 5, 10, 20, 30, and 60 minutes after mAb 806–Cy3 internalization are shown. (B) Mean ratio of intracellular to membrane
(black) and membrane to intracellular (red) fluorescence of untransfected wt cells ± SEM (n = 4), over time. Untransfected cells show gradual increase in
intracellular fluorescence with a concurrent decrease in membrane associated fluorescence. (C) Mean ratio of intracellular to membrane (black) and membrane to
intracellular (red) fluorescence of DynK44A-transfected cells ± SEM (n = 6), over time. DynK44A-transfected cells show little accumulation of intracellular
fluorescence while sustaining high membrane fluorescence intensity. Scale bar, 20 m. Refer to Supplemental data for Video W2.
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between mAb 806 and EEA1 decreased (Figure 4B; 60 min-
utes). This suggests that the majority of fluorescently labeled
antibody may have moved out of early endocytic compartments
by this time. Similar results were also observed for mAb 528
(data not shown). There was no evidence of endoplasmic
reticulum/Golgi involvement in mAb 806 internalization.
Lysosomal Localization of Internalized mAb 806 in
A431 Cells
Lysosomal localization of internalized mAb 806 was also
assessed following binding to the wt EGFR in A431 cells. Im-
munofluorescence staining with a lysosomal-specific antibody
(anti-LAMP1) showed specific cytoplasmic staining which
did not overlap with noninternalized mAb 806 (Figure 5A;
0 minutes merge). Following incubation at 37jC for 60 min-
utes, mAb 806 was observed to colocalize with LAMP1 as in-
dicated in the merged images (Figure 5A; 60 minutes).
Time-lapse imaging of mAb 806 targeting to lysosomal
compartments was also investigated in A431 cells by
assessing the extent of mAb 806 colocalization with the
lysosomal glycoprotein 120 (lgp-120), an integral mem-
brane protein located in lysosomal compartments [35].
A431 cells were transfected with lgp-120–GFP and posi-
tively transfected cells were imaged live at 37jC following
preincubation with mAb 806–Cy3 (Figure 5B). At time 0
(Figure 5B; 0 minutes), mAb 806–Cy3 (red) is seen only on
the cell surface as expected, whereas cells positively
transfected for lgp-120–GFP displayed intracellular staining
for lysosomal compartments (Figure 5B; 0 minutes; green
fluorescence). At 30 minutes, mAb 806, seen as small
punctate structures, rapidly migrated in an inward centrif-
ugal motion toward the perinuclear region in transfected and
untransfected cells (Figure 5B; 30 minutes). Initially, these
structures did not colocalize with lgp-120–GFP (Figure 5B;
30 minutes). However, following longer incubation at 37jC,
areas of colocalization between mAb 806–Cy3 and lgp-
120–GFP were observed (Figure 5B; arrows), with maximal
colocalization occurring at 60 minutes in this experiment.
Electron Microscopic Analysis of mAb 806 Internalization
and Intracellular Trafficking
To support the immunofluorescence data, we also in-
vestigated the localization of internalized mAb 806 fol-
lowing binding to the wt EGFR on A431 cells by electron
microscopy. Following 5 minutes of incubation at 37jC,
gold particles, corresponding to mAb 806, were observed
in structures resembling clathrin-coated pits (Figure 6, A and
B; closed arrowheads). Gold particles were also detected in
free clathrin-coated vesicles after antibody was allowed to
internalize for 10 minutes (Figure 6C). No gold particles were
Figure 4. (A) Time-lapse microscopy of internalization and colocalization of mAb 806–Cy3 (red) and transferrin –FITC (green) in A431 cells. Internalization of mAb
806 at 2 minutes is represented by yellow arrowheads. Colocalization is indicated by white arrows. Scale bar, 20 m. Refer to Supplemental data for Video W3. (B)
Colocalization of mAb 806–Cy3 (red) and EEA1 (green) in A431 cells. Following internalization of mAb 806, cells were fixed at different time intervals and stained
for EEA1 localization. Colocalization is indicated by arrows in the merged images. Scale bar, 20 m.
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observed in structures resembling caveolae (Figure 6D;
open arrowheads).
Following longer incubation at 37jC, mAb 806 gold
particles were observed in large tubular–vesicular structures
resembling early endocytic compartments (Figure 6E ). After
30 minutes, mAb 806 was localized to structures resembling
multivesticular endosomes (Figure 6F ). Gold particles were
readily observed on the internal vesicles of multivesticular
endosomes, suggesting eventual localization and degrada-
tion in lysosomal compartments. These observations are
therefore consistent with the immunofluorescence micros-
copy data that indicated colocalization of mAb 806 initially
with EEA1 and subsequently with LAMP1 and lgp-120 be-
tween 30 and 60 minutes.
Biodistribution of 111In/125I–Labeled mAb 806 in A431
Tumor–Bearing Nude Mice
MAb 806 was successfully trace-radiolabeled with both
111In and 125I, and the quality of the radioconjugates was
assessed before commencement of the biodistribution study.
The instant thin-layer chromatography–determined radio-
chemical purity of 125I- and 111In-labeled mAb 806 was
99.6% and 99.5%, respectively. The specific activity for each
radioconjugate was 0.99 and 0.73 mCi/mg for 125I- and 111In-
labeled mAb 806, respectively. To confirm retention of im-
munoreactivity following radiolabeling, binding of 125I- and
111In-labeled mAb 806 to antigen-positive A431 cells was
determined. The number of molecules of radiolabeled anti-
body bound to A431 cells was approximately equivalent for
125I- and 111In-labeled mAb 806 (3.14  105 and 3.89  105,
respectively) and comparable to that previously published
[10]. 125I- and 111In-labeled control isotype–matched mAb
100-310 demonstrated no immunoreactivity with A431 cells,
as expected.
The in vivo biodistribution and targeting of radiolabeled
antibody was investigated in A431 tumor-bearing mice.
Groups of mice (n = 4) bearing A431 tumors (70 mm3)
were injected IV with radiolabeled mAb 806 before harvest
Figure 5. Lysosomal localization of mAb 806–Cy3 in A431 Cells. (A) Preincubated mAb 806–Cy3 (red) was allowed to internalize for 60 minutes at 37jC. Cells
were subsequently fixed and stained for LAMP1 (green). Colocalization is indicated by arrows in the merged images. Scale bar, 20 m. (B) Time-lapse microscopy
of internalization and colocalization of mAb 806–Cy3 (red) and lgp-120–GFP (green) in A341 cells. Sequential images of transfected A431 cells are shown at 0,
30, 45, and 60 minutes. Colocalization is indicated by the arrows. Scale bar, 20 m. Refer to Supplemental data for Video W4.
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of normal tissue, blood, and tumor 4, 24, 48, 72, and 168 hours
postinjection. Table 1 presents the % ID/g of 125I- and 111In-
labeledmAb806 in A431 tumors and blood for each time point.
Following injection, the % ID/g of 111In-mAb 806 in A431
xenografts gradually increased before peaking at 48 hours
after antibody injection (44.9%) (Figure 7A). Subsequently,
the level of 111In-mAb 806 detected in the tumor slowly
decreased over the course of the study and, at 168 hours
postinjection, the % ID/g was 24%. In contrast, the maximum
uptake of 125I-mAb 806 in tumors (13.7%) occurred 4 hours
after antibody injection and gradually decreased with time
(2.5% at 168 hours postinjection) (Figure 7A). Tumor uptake
was superior for the 111In-labeled mAb 806, at all time points
studied. For example, at 48 hours, the % ID/g of 111In was
more than 6-fold higher than 125I (44.9% vs 7.2% respec-
tively, P < .02). Furthermore, as much as a 9-fold greater
uptake of 111In-labeled mAb 806 compared to 125I-labeled
mAb 806 was detected 72 hours postinjection (36.6% vs
4.4%, respectively) (P < .003) (Figure 7A). The blood levels
of both isotopes closely approximated each other throughout
the study, declining progressively over time (Figure 7A),
indicating that antibody serum half life had no effect on tumor
targeting. The tumor/blood ratio for 111In-labeled mAb 806
peaked at 4.67 ± 0.66 at 168 hours, compared with 0.56 ±
0.11 at 24 hours for 125I-mAb 806.
The biodistribution of radiolabeled mAb 806 in normal
tissue was also analyzed and results at 4, 24, 48, 72, and 168
hours after injection of the antibody are presented in Fig-
ure 7B. The %ID/g in all normal tissues analyzed was less
than 10% at all time points. The percentage uptake of
111In-labeled mAb 806 was higher in the liver, spleen, and
kidney than those of 125I-labeled mAb 806 at all time points.
This may reflect differences in catabolism and biochemical
processing of iodotyrosine derivatives versus 111In-DTPA–
labeled metabolites. Normal tissue distribution of the con-
trol isotype–matched 100-310 antibody labeled with 125I and
111In was also assessed at 24 hours postinjection (Figure 7B).
Higher levels of 111In-mAb 100-310 uptake were noted in
both the liver and the spleen. This most likely represents
accumulation of free 111In in these organs indicating that
radiolabeled mAb 100-310 may be less stable. Importantly,
uptake of 111In-mAb 100-310 was only 7.5% in tumor tissue
compared to 36% uptake of 111In-labeled mAb 806, 24 hours
postinjection (Figure 7, A and B). Tumor/blood ratios of 0.7
and 0.4 for 111In- and 125I-labeled mAb 100-310, respectively,
were detected 24 hours postinjection, further indicating non-
specific tumor tissue uptake of this antibody.
Discussion
The use of mAbs that target growth factor receptors such as
immunotherapeutic agents has been the subject of intensive
investigation by numerous groups. Indeed, many such anti-
bodies are currently being assessed in advanced clinical
trials or, in the case of Herceptin (anti-ErbB2) [36], Erbitux,
and Vectabix (anti-EGFR) [4], have been approved for
treatment of patients with advanced metastatic disease.
Furthermore, there is a growing body of data highlighting
the potential use of antibodies as carriers for radioisotopes
and toxins [21–24]. These conjugates have demonstrable
antitumor activity in experimental models and thereby war-
rant further investigation as to their suitability for clinical use.
Binding of such antibody constructs to their cognate receptor
would potentially elicit both receptor inhibition and the induc-
tion of cytotoxic effects attributable to the toxin or radioiso-
tope. Indeed, the inhibition of receptor activity may in fact
enhance the cytotoxicity of the compound used if chosen
correctly. The ability of an antibody to modulate the activity of
its target receptor is critical to its function, likewise, the type
of radioisotope or drug/toxin best suited to a particular
antibody is predominantly determined by its fate following
binding to its cognate receptor. Accordingly, antibody inter-
nalization and intracellular retention are important criteria for
assessing the potential of a therapeutic agent being consid-
ered for conjugation with a toxin or radioisotope conjugate.
Figure 6. Electron microscopic analysis of mAb 806 internalization and in-
tracellular trafficking following binding to amplified EGFR in A431 cells. (A–B)
Gold particles (arrowheads) were detected in deeply invaginated clathrin-
coated pits after 5 minutes at 37jC. (C) Gold particles were also localized in
free clathrin–coated vesicles within the cytoplasm. (D) No gold particles were
present in structures resembling caveolae (open arrowheads) at 5 minutes.
(E) Gold particles were also detected in tubular – vesicular structures resem-
bling early endosomes after 10 to 15 minutes at 37jC. (F) After 30 minutes,
gold particles were localized to multivesicular bodies. Scale bar, 100 nm.
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The unique specificity of mAb 806, and its proven efficacy
in animal models against xenografts expressing either the
de2–7 EGFR or wt EGFR, makes it an ideal reagent for
translation into a clinical setting. This study presents the
internalization and intracellular trafficking of mAb 806 in
A431 cells, a well-characterized cell line that overexpresses
the wt EGFR, as the main aim of this study was to determine
the intracellular trafficking pathway of mAb 806 that could be
exploited for therapeutic payload delivery. The A431 cell line
has been extensively studied as a model system for the
study of wt EGFR biology and for preclinical evaluation of wt
EGFR therapeutics [1,2,3,31]. Using live cell fluorescent
microscopy, we found that mAb 806 undergoes rapid inter-
nalization following binding to the wt EGFR overexpressed
on A431 cells. Internalization of mAb 806 was reproducible in
the HN5 squamous carcinoma cell line. Internalization of
mAb 806 was dynamin-dependent as was also recently
shown for anti–ErbB2 antibody internalization [37]. Indeed,
dynamin is required for a number of endocytic processes
such as clathrin-mediated endocytosis, endocytosis through
caveolae, phagocytosis, and macropinocytosis [38,39].
However, immunoelectron microscopy clearly identified
mAb 806 to be localized in structures morphologically re-
sembling clathrin-coated pits and vesicles. Following inter-
nalization, mAb 806 was detected in early endocytic
compartments and at later time points (30 and 60 minutes)
in lysosomal compartments. Indeed, for an antibody to act as
a carrier for delivery of increased quantities of radioisotope or
toxin to the tumor site over time, its ability to internalize,
traffic, and accumulate in lysosomal compartments is cru-
cial. Therefore, the retention of mAb 806 within the target
tumor cells makes it an ideal candidate for radioisotope or
toxin conjugation.
Given that mAb 806 is known to recognize a transitional
form of the EGFR that exists as it switches from the tethered
inactive form to the untethered form [17,18], our data show-
ing rapid mAb 806 internalization also suggests that the
inactive intermediate conformation of the EGFR can undergo
internalization. This unique specificity of mAb 806 arises
from its recognition of an epitope buried at the CR1/CR2
interface in the active dimer form of the EGFR, which is
partially buried in the inactive tethered configuration [18].
Given that this epitope is buried in both conformations,
binding of mAb 806 to either the tethered or the untethered
conformation is prevented. MAb 806 binding only occurs
during the transition from the tethered inactive form of the
EGFR to the untethered form [18]. Moreover, in this inter-
mediate untethered state, the mAb 806 epitope is exposed,
allowing antibody binding [17]. This transitional state
accounts for only 5% to 10% of total EGFR on the cell
surface at a given time, which corresponds to the proportion
of receptor recognized by mAb 806 in cells such as A431 that
overexpress the EGFR. Furthermore, it is likely that over
longer periods of time, a greater proportion of the cell surface
EGFR may be targeted by mAb 806 as the receptor con-
tinues to untether. This cumulative uptake of mAb 806 by
tumor cells has been shown in animal model studies, and in
human tumors in our first-in-man clinical trial [16,40]. There-
fore, mAb 806 binding almost certainly traps the EGFR in this
transitional state preventing dimerization and subsequent
activation. Indeed, a recent study investigating the antitumor
activity of the ErbB2 antibody, 2C4, showed that this antibody
is capable of blocking formation of ErbB2 homo- or hetero-
dimers [41]. Following binding of 2C4 to ErbB2 monomers,
this antibody was able to cause significant downregulation of
ErbB2, indicating that monomeric receptors are also capable
of undergoing successful internalization [41]. This down-
regulation of monomeric ErbB2, in turn, has been linked to
the significant efficacy of mAb 2C4 in vivo against ErbB2
expressing breast and prostate cancer xenografts [42].
Therefore, our data suggest that transient configurations of
the EGFR are also capable of undergoing successful inter-
nalization even when inactive, which can subsequently lead
to an antitumor response.
Because internalizing antibodies can be used as diag-
nostic and therapeutic tools, and having established that
mAb 806 is able to internalize following binding to a propor-
tion of the EGFR, its potential as a carrier for radioisotopes/
toxins was evaluated in an in vivo A431 tumor model. The
%ID/g of 111In-labeled mAb 806 in A431 tumor xenografts
was significantly greater than that for 125I-labeled mAb 806 at
all time points. Whereas initial targeting of both mAb 806
conjugates is presumably identical in this tumor model, the
differences in tumor retention of 111In and 125I indicate that
111In is a more accurate reflection of true uptake and reten-
tion of mAb 806 in tumor xenografts. This data would also
Table 1. Biodistribution of 125I- and 111In –CHX-AW-DTPA–Labeled mAb 806 in A431 Xenografted BALB/c Nude Mice*.
Timey (Hours) nz % ID/g§ in A431 Tumor (Mean ± SD) % ID/g in Blood (Mean ± SD)
111In 125I 111In 125I
4 4 21.8 ± 6.1 13.7 ± 3.3 30.9 ± 1.9 29.8 ± 1.7
24 4 36.4 ± 10.0 9.9 ± 3.5 19.3 ± 2.3 18.6 ± 2.2
48 4 44.9 ± 11.4 7.2 ± 2.3 12.6 ± 1.7 12.5 ± 1.7
72 4 36.6 ± 8.2 4.5 ± 1.2 13.2 ± 1.9 10.7 ± 1.2
168 4 23.6 ± 6.3 2.5 ± 0.9 5.2 ± 1.7 4.7 ± 1.6
*Mice bearing A431 tumors received tail vein injections containing 5 mCi of both 125I- and 111In–CHX-AW-DPTA– labeled mAb 806 (total, 10 mg of antibody; 10 mCi)
on day 0. Groups of four mice were sacrificed at the indicated times. The blood was collected, tumors removed, blotted dry, and weighed. Radioactivity was
measured.
yTime in hours after injection of antibody.
zNumber of mice per time point.
§% ID/g was calculated. Data are presented as mean ± SD.
Internalization and Trafficking of mAb806 Perera et al. 1107
Neoplasia . Vol. 9, No. 12, 2007
indicate that 111In (or a nonresidualizing tracer) would be a
better candidate for conjugation to mAb 806 for diagnostic
purposes, such as the identification of occult tumors. The
reasons for the difference in tumor retention of each isotope
are well established. Whereas the metabolites of iodine
moieties are rapidly excreted from the cell [43], slower
catabolism of the 111In-DTPA–labeled metabolites results
in accumulation and retention in lysosomal compartments for
longer periods [44]. Therefore, the ability of mAb 806 to
rapidly internalize following binding to a transient conforma-
tion of the EGFR can successfully be translated into an
in vivo setting resulting in specific targeting of tumor tissue.
In addition, the uptake and retention of mAb 806 in wt EGFR
tumor is comparable to the maximum uptake of antibodies
that target all wt EGFR on the surface of the cell (and block
ligand binding) such as Cetuximab. This highlights the
importance of normal wt EGFR turnover on the surface of
cancer cells in vivo, which increases the available transitional
form of the EGFR that can bind to mAb 806 with time.
Whereas gamma-emitting isotopes such as 111In are not
routinely used for therapeutic purposes, they remain impor-
tant predictive agents for the behavior of other radiometals
such as Yttrium-90 (90Y) or Lutetium-177 (177Lu). For exam-
ple, 90Y is a high-energy beta emitter with a particle range of
up to 12 mm and has been extensively used for radio-
immunotherapy with several antibody–antigen systems in
Figure 7. Biodistribution of mAb 806. (A) Biodistribution (% ID/g) of 111In–CHX-AW-DTPA– (closed symbols) and 125I- (open symbols) labeled mAb 806 in A431
tumor xenografts and blood from BALB/c nude mice. Twenty mice received IV injections of a total of 10 g (10 Ci) of radiolabeled mAb 806. Means for each time
point consisting of data from four mice are shown. Bars, SD. Data are presented as: 111In –blood (.); 111In –A431 tumor (n); 125I –blood (o); 125I –A431 tumor (5).
(B) Biodistribution of 125I- (white bar) and 111In–CHX-AW-DTPA– (black bar) labeled mAb 806 in normal murine tissues, A431 tumors, and blood at 4, 24, 48, 72,
and 168 hours after IV administration (10 Ci, 10 g total mAb 806) of BALB/c nude mice. The biodistribution of 125I- (white bar) and 111In–CHX-AW-DTPA– (black
bar) labeled control mAb 100-310 was also assessed at 24 hours postinjection. Data from groups of four mice are expressed as mean % ID/g. Bars, SD.
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patients with a variety of cancers [45–49]. 90Y also has a
long residence time in tumors, thereby enabling delivery of a
large radiation dose to the tumor cell. Accordingly, 111In is
often used as a surrogate gamma-imaging isotope to predict
suitable therapeutic doses for other radiometals such as 90Y,
as it possesses comparable biodistribution and clearance
rates [27]. Therefore, the specific targeting of 111In-labeled
mAb 806 to tumor tissue indicates that similar targeting of
a 90Y or 177Lu conjugate of mAb 806 may enable delivery
of a sufficient therapeutic dose to produce effective tumor
cell killing and subsequent tumor regression with negligi-
ble side effects to normal tissue. Such targeted delivery of
antibody–radioisotope conjugates is not possible with cur-
rently approved anti–EGFR or –ErbB2 antibodies such as
Cetuximab, Panitumumab, and Herceptin, as these agents
can bind to receptor expressed in normal tissue.
Collectively, these studies establish that mAb 806 is able
to rapidly internalize, following binding to a transient form of
the EGFR. Accumulation of mAb 806 in lysosomal compart-
ments makes it an ideal candidate for construction of mAb
806 conjugates linked to radioisotopes, drugs, or toxins.
Furthermore, mAb 806 has no detectable binding to wt
EGFR expressed on normal tissues possessing physiologi-
cal levels of receptor such as the liver, skin, and gastroin-
testinal tract and, therefore, would be unlikely to cause
normal tissue toxicity, which is dose-limiting for current
anti–wt EGFR antibodies and kinase inhibitors. We have
generated a chimeric version of this antibody [40], and this
antibody has recently completed a Phase I first-in-man trial,
confirming the tumor selectivity of ch806 and lack of normal
tissue binding [16]. These characteristics along with the
unique specificity of mAb 806 make it an ideal therapeutic
agent that can be used for both diagnostic and therapeutic
purposes in patients with EGFR-positive malignancies.
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